Aristo Bio-Tech & Lifescience Ltd Financials
Company Logo

Aristo Bio-Tech & Lifescience Ltd Financial Statement

Aristo Bio-Tech & Lifescience Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Invest in Aristo Bio-Tech & Lifescience Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Aristo Bio-Tech & Lifescience Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual245.15
Operating Expenses Annual236.66
Operating Profit Annual8.67
Interest Annual1.69
Depreciation1.57
Net Profit Annual3.90
Tax Annual1.51

Aristo Bio-Tech & Lifescience Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning1.85
Cash Flow from Operations7.60
Cash Flow from Investing-6.61
Cash Flow from Financing-2.21
Cash Flow at the End0.64

Aristo Bio-Tech & Lifescience Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)3.54
PBIT Margin (%)2.90
PBT Margin (%)1.19
Net PROFIT Margin (%)1.59
Return On Networth / Equity (%)12.23
Return On Networth /Employed (%)13.25
Return On Assets (%)7.29
Total Debt / Equity (X)0.68
Asset Turnover Ratio (%)4.58

Aristo Bio-Tech & Lifescience Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual21.68
Total Current Assets Annual105.03
Non Current Assets Annual22.26
Total Shareholders Funds Annual33.61
Total Assets Annual127.29

Aristo Bio-Tech & Lifescience Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 24, 2024, Aristo Bio-Tech & Lifescience Ltd has a market capitalization of 42.51 Cr. Value Research classifies it as a Micro-Cap company.
No, Aristo Bio-Tech & Lifescience Ltd is not debt-free with a debt-to-equity ratio of 0.62.
In FY 2023 , Aristo Bio-Tech & Lifescience Ltd recorded a total revenue of approximately 245.15 Cr marking a significant milestone in the company's financial performance.
Aristo Bio-Tech & Lifescience Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and 0.2% annually, respectively..
Aristo Bio-Tech & Lifescience Ltd's current PE ratio is 10.90.
Aristo Bio-Tech & Lifescience Ltd's ROCE averaged 12.7% from the FY ending March 2022 to 2024, with a median of 13.0%. It peaked at 14.2% in March 2023, reflecting strong capital efficiency over the period..
Aristo Bio-Tech & Lifescience Ltd's latest EBIT is Rs. 7.10 Cr, surpassing the average EBIT of Rs. 6.31 Cr over the 5 years..